# Microneedle Solutions

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/microneedle-solutions

- Industry: Medical Devices & Equipment
- Headquarters: Leeds, UK
- Website: www.microneedlesolutions.com/
- Latest round: Seed (Mar 2, 2026)
- Investors on record: 5

## About

Microneedle Solutions Ltd, based in the UK, develops innovative vaccine delivery solutions, focusing on enhancing accessibility and convenience through its microneedle vaccine patch technology.Microneedle Solutions Ltd specializes in vaccine delivery innovations, particularly the microneedle vaccine patch. Headquartered in Leeds, UK, the company has engaged in one notable deal as of March 2, 2026, securing funding to propel its operations forward. The company does not have any known subsidiaries or parent companies, and there are no mentions of strategic pivots in its business model. The founder's history is not specified in the available information.MNS specializes in the development and distribution of innovative vaccine delivery solutions, primarily through its flagship product, the microneedle vaccine patch. This non-invasive and thermally stable patch simplifies and enhances the vaccination experience by enabling self-administration in non-clinical settings, focusing on remote and underserved populations. Clients include healthcare providers, governmental health organizations, and individuals seeking accessible vaccination options in various geographical areas.The revenue model of MNS centers on direct sales of its microneedle vaccine patches to healthcare organizations and government entities, facilitating sustainable partnerships in the public health sector. The company engages in B2B transactions, collaborating with distributors to broaden its reach within the healthcare market. Pricing structures are determined by contracts reflecting the scale of distribution and intended usage, with established partnerships and distribution agreements integral to revenue generation.In March 2026, Microneedle Solutions Ltd raised an undisclosed amount of Seed funding from new investors including Pioneer Group, SFC Capital, Cambridge Angels Group, Southern Angel Investors Club, and Sheffield Angels. This funding will be used to advance its lead asset powered by its proprietary Miracus technology into first-in-human clinical trials in collaboration with the National Health Service in 2026. The company aims to expand its market reach and intends to launch new products designed to address health inequalities globally.

## Funding rounds

- Seed, Mar 2, 2026 — Cambridge Angels Group, SFC Capital, Southern Angel Investors Club, Pioneer Group, Sheffield Angels

## Investors

- Cambridge Angels Group — Seed
- SFC Capital (https://capitalatlas.ai/funds/sfc-capital) — Seed
- Southern Angel Investors Club — Seed
- Pioneer Group (https://capitalatlas.ai/funds/pioneer-group) — Seed
- Sheffield Angels — Seed